Alexander Turchin

Alexander Turchin

Auto-generated profile, based on publicly available information

Alexander Turchin

Brigham and Women’s Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
ATAlexander Turchin
Alexander Turchin
SMStanislav Masharsky
Stanislav Masharsky
MZMarinka Zitnik
Marinka Zitnik

15 August 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
HZHuabing Zhang
Huabing Zhang
JPJorge Plutzky
Jorge Plutzky
MSMaria Shubina
Maria Shubina
ATAlexander Turchin
Alexander Turchin
Many patients discontinue statin treatment, often after having a possible adverse reaction. The risks and benefits of continued statin therapy after an adverse reaction are not known. To examine the relationship between continuation of statin therapy (any prescription within 12 months after an adverse reaction) and clinical outcomes. Retrospective cohort study. Primary care practices affiliated with 2 academic medical centers. Patients with a presumed adverse reaction to a statin between 2000 and 2011. Information on adverse reactions to statins was obtained from structured electronic medical record data or natural-language processing of narrative provider notes. The primary composite outcome was time to a cardiovascular event (myocardial infarction or stroke) or death. Most (81%) of the adverse reactions to statins were identified from the text of electronic provider notes. Among 28 266 study patients, 19 989 (70.7%) continued receiving statin prescriptions after the adverse reaction. Four years after the presumed adverse event, the cumulative incidence of the composite primary outcome was 12.2% for patients with continued statin prescriptions, compared with 13.9% for those without them (difference, 1.7% [95% CI, 0.8% to 2.7%]; P < 0.001). In a secondary analysis of 7604 patients for whom a different statin was prescribed after the adverse reaction, 2014 (26.5%) had a documented adverse reaction to the second statin, but 1696 (84.2%) of those patients continued receiving statin prescriptions. The risk for recurrent adverse reactions to statins could not be established for the entire sample. It was also not possible to determine whether patients actually took the statins. Continued statin prescriptions after an adverse reaction were associated with a lower incidence of death and cardiovascular events. Chinese National Key Program of Clinical Science, National Natural Science Foundation of China, and Young Scientific Research Fund of Peking Union Medical College Hospital.

1 February 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
CBC. Justin Brown
C. Justin Brown
LCLee-Shing Chang
Lee-Shing Chang
NHNaoshi Hosomura
Naoshi Hosomura
SMShervin Malmasi
Shervin Malmasi
FMFritha Morrison
Fritha Morrison
ATAlexander Turchin
Alexander Turchin
Importance: Many patients at high cardiovascular risk—women more commonly than men—are not receiving statins. Anecdotally, it is common for patients to not accept statin therapy recommendations by their clinicians. However, population-based data on nonacceptance of statin therapy by patients are lacking.Objectives: To evaluate sex disparities in nonacceptance of statin therapy and assess their association with low-density lipoprotein (LDL) cholesterol control.Design, Setting, and Participants: A retrospective cohort study was conducted from January 1, 2019, to December 31, 2022, of statin-naive patients with atherosclerotic cardiovascular disease, diabetes, or LDL cholesterol levels of 190 mg/dL (to convert to millimoles per liter, multiply by 0.0259) or more who were treated at Mass General Brigham between January 1, 2000, and December 31, 2018.Exposure: Recommendation of statin therapy by the patient’s clinician, ascertained from the combination of electronic health record prescription data and natural language processing of electronic clinician notes.Main Outcomes and Measures: Time to achieve an LDL cholesterol level of less than 100 mg/dL.Results: Of 24 212 study patients (mean [SD] age, 58.8 [13.0] years; 12 294 women [50.8%]), 5308 (21.9%) did not accept the initial recommendation of statin therapy. Nonacceptance of statin therapy was more common among women than men (24.1% [2957 of 12 294] vs 19.7% [2351 of 11 918]; P < .001) and was similarly higher in every subgroup in the analysis stratified by comorbidities. In multivariable analysis, female sex was associated with lower odds of statin therapy acceptance (0.82 [95% CI, 0.78-0.88]). Patients who did vs did not accept a statin therapy recommendation achieved an LDL cholesterol level of less than 100 mg/dL over a median of 1.5 years (IQR, 0.4-5.5 years) vs 4.4 years (IQR, 1.3-11.1 years) (P < .001). In a multivariable analysis adjusted for demographic characteristics and comorbidities, nonacceptance of statin therapy was associated with a longer time to achieve an LDL cholesterol level of less than 100 mg/dL (hazard ratio, 0.57 [95% CI, 0.55-0.60]).Conclusions and Relevance: This cohort study suggests that nonacceptance of a statin therapy recommendation was common among patients at high cardiovascular risk and was particularly common among women. It was associated with significantly higher LDL cholesterol levels, potentially increasing the risk for cardiovascular events. Further research is needed to understand the reasons for nonacceptance of statin therapy by patients and to develop methods to ensure that all patients receive optimal therapy in accordance with their preferences and priorities.

14 September 2017 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
NHN. Hosomura
N. Hosomura
SMS. Malmasi
S. Malmasi
DTD. Timerman
D. Timerman
VLV. J. Lei
V. J. Lei
HZH. Zhang
H. Zhang
ATA. Turchin
A. Turchin

13 June 2017 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
FMFritha J.R. Morrison
Fritha J.R. Morrison
MMMaryam Movassaghian
Maryam Movassaghian
ESEllen W. Seely
Ellen W. Seely
ACAshley Curran
Ashley Curran
MSMaria Shubina
Maria Shubina
ATAlexander Turchin
Alexander Turchin

19 March 2021 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
PDF file
ATAlexander Turchin
Alexander Turchin
LBLuisa F. Florez Builes
Luisa F. Florez Builes
Background: Real-world evidence research plays an increasingly important role in diabetes care. However, a large fraction of real-world data are “locked” in narrative format. Natural language processing (NLP) technology offers a solution for analysis of narrative electronic data. Methods: We conducted a systematic review of studies of NLP technology focused on diabetes. Articles published prior to June 2020 were included. Results: We included 38 studies in the analysis. The majority (24; 63.2%) described only development of NLP tools; the remainder used NLP tools to conduct clinical research. A large fraction (17; 44.7%) of studies focused on identification of patients with diabetes; the rest covered a broad range of subjects that included hypoglycemia, lifestyle counseling, diabetic kidney disease, insulin therapy and others. The mean F1 score for all studies where it was available was 0.882. It tended to be lower (0.817) in studies of more linguistically complex concepts. Seven studies reported findings with potential implications for improving delivery of diabetes care. Conclusion: Research in NLP technology to study diabetes is growing quickly, although challenges (e.g. in analysis of more linguistically complex concepts) remain. Its potential to deliver evidence on treatment and improving quality of diabetes care is demonstrated by a number of studies. Further growth in this area would be aided by deeper collaboration between developers and end-users of natural language processing tools as well as by broader sharing of the tools themselves and related resources.